

Brompton Global Healthcare Income & Growth ETF
Summary of Investment Portfolio as at December 31, 2022

Total Net Asset Value \$ 65,550,486

Portfolio Composition	% of Net Asset Value
Europe	
Denmark	
Pharmaceuticals	5.3%
Great Britain	
Pharmaceuticals	7.3%
Total Europe	12.6%
North America	
United States	
Pharmaceuticals	27.3%
Managed Healthcare	13.0%
Healthcare Distributors	10.7%
Biotechnology	10.6%
Healthcare Services	10.3%
Healthcare Equipment	6.7%
Life Sciences Tools and Services	6.6%
Healthcare Facilities	2.5%
Total North America	87.7%
Cash & short-term inv.	0.5%
Other net liabilities	(0.8%)
Total Net Asset Value	100.0%

Holdings	% of Net Asset Value
Merck & Co Inc	6.5%
UnitedHealth Group Inc	6.0%
Eli Lilly and Co	6.0%
Cardinal Health Inc	5.8%
Pfizer Inc	5.6%
Cigna Corp	5.5%
AstraZeneca PLC	5.3%
Novo Nordisk A/S	5.3%
Elevance Health Inc	5.0%
Mckesson Corp	4.9%
Danaher Corp	4.9%
CVS Health Corp	4.8%
Thermo Fisher Scientific Inc	4.8%
Bristol-Myers Squibb Co	4.7%
Johnson & Johnson	4.5%
Gilead Sciences Inc	4.1%
Abbie Inc	4.0%
HCA Healthcare Inc	2.5%
Amgen Inc	2.5%
GSK plc	2.0%
Centene Corp	2.0%
Stryker Corp	1.8%
Agilent Technologies Inc	1.8%
Cash & short-term inv.	0.5%
(blank)	
Total	100.8%

The investment portfolio may change due to ongoing portfolio transactions of the investment fund. Quarterly updates are available on the Fund's website at www.bromptongroup.com within 60 days of each quarter end.